Anne Bruinvels joins EPEMED as executive director

Targeted with growing start-up organisation and building its strategic framework

The European Personalised Medicine Diagnostics Association (EPEMED) has appointed Anne Bruinvels, an entrepreneur in personalised healthcare, as executive director and board member.

Bruinvels will be responsible for growing the start-up organisation and, together with the board of directors, for building its strategic framework in creating guidance for all those involved in progressing personalised medicine with an emphasis on European market challenges.

‘I'm delighted to join EPEMED's board and to lead the association to facilitate the development and introduction of personalised medicine in Europe. I'm looking forward to working with the different parties worldwide involved in making real progress in this field,’ said Bruinvels.

Bruinvels started her work in personalised medicine more than 10 years ago. She previously founded Elixior, a personalised healthcare advisory company and prior to that Curidium, a personalised medicine company identifying companion diagnostics and therapeutics to treat patients with central nervous system disorders. She was Curidium's ceo for more than six years and raised several rounds of funding before taking the company public on the AIM of the London Stock Exchange.

Bruinvels has also worked in research for various pharmaceutical companies, including SmithKline Beecham, Wyeth and Sandoz Pharma.

You may also like

Regulatory

Standard proposed to clarify endotoxin testing for single-use systems

The guide will address variability when assessing bacterial endotoxins on large-scale pharmaceutical equipment
Research & Development

Weight loss drugs such as Ozempic may prevent stroke and reduce brain injury related complications

Three studies presented at the Society of NeuroInterventional Surgery's (SNIS) 22nd Annual Meeting discussed whether using GLP-1 inhibitors could lessen the impacts of stroke and related brain injuries or reduce the risk of stroke altogether
Finance

Sanofi completes acquisition of Blueprint Medicines

Sanofi announces the completion of its acquisition of Blueprint Medicines Corporation, adding to its portfolio a commercialised medicine and the expertise of a company specialising in systemic mastocytosis (SM) and other KIT-driven diseases
Personal Protection

Almost 60% of workplace injuries from harmful substances are burns

Chemical burns continue to be the leading type of non-fatal injury caused by exposure to or contact with harmful substances in workplaces across Great Britain
Regulatory

AlzeCure's pain project ACD440 granted orphan drug status in the US by the FDA

AlzeCure Pharma announces that the US Food and Drug Administration (FDA) has granted the company's application for orphan drug status for the clinical pain candidate drug ACD440
Finance

Evestia Clinical to merge with Atlantic Research Group

The merger delivers on Evestia Clinical’s strategy of targeted growth through the expansion of services, enhanced technology and broadened geographical reach
Manufacturing

Molecular Devices unveils next-generation SpectraMax Multi-Mode Microplate Readers

Honouring a legacy of product line reliability and strength, the SpectraMax Multi-Mode Microplate Readers have been transformed with next-generation innovation to improve research capabilities and provide unparalleled flexibility for a wide range of assays and applications
Subscribe now